Sector
PharmaceuticalsOpen
₹255Prev. Close
₹254.85Turnover(Lac.)
₹305.03Day's High
₹260Day's Low
₹24752 Week's High
₹307.9852 Week's Low
₹155.05Book Value
₹257.85Face Value
₹2Mkt Cap (₹ Cr.)
3,915.66P/E
0EPS
0Divi. Yield
023 Aug 2024
12:00 AM
AGM
Announcement Date: 23 Aug, 2024
16 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 31.36 | 31.36 | 31.36 | 31.36 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 4,021.22 | 4,082.95 | 4,200.42 | 4,643.26 |
Net Worth | 4,052.58 | 4,114.31 | 4,231.78 | 4,674.62 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 208.01 | 580.74 | 474.46 | 451.49 |
yoy growth (%) | -64.18 | 22.4 | 5.08 | 6,529.8 |
Raw materials | -108.44 | -200.11 | -155.31 | -142.07 |
As % of sales | 52.13 | 34.45 | 32.73 | 31.46 |
Employee costs | -59.4 | -88.87 | -61.67 | -66.76 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -168.69 | 55.46 | 62.17 | 43.91 |
Depreciation | -143.21 | -140.65 | -134.45 | -135.85 |
Tax paid | -64.12 | -16.94 | -25.1 | -19.67 |
Working capital | 0.78 | 29.87 | 52.04 | 419.05 |
Other operating items |
No Record Found
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 2,711.5 | 2,615.77 | 2,412.92 | 2,140.69 | 1,912.03 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 2,711.5 | 2,615.77 | 2,412.92 | 2,140.69 | 1,912.03 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 21.68 | 28.21 | 27.77 | 43.42 | 38.45 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,672 | 93.86 | 4,01,288.77 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,835 | 82.12 | 1,81,397.34 | 667 | 0.44 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,485 | 24.92 | 1,19,948.65 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,314.2 | 59.26 | 1,12,127.01 | 474 | 0.18 | 2,385 | 224.34 |
Mankind Pharma Ltd MANKIND | 2,578.3 | 56.47 | 1,06,401.47 | 382.46 | 0 | 2,126.59 | 354.71 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Janmejay R Vyas
Whole-time Director
Deohooti J Vyas
Managing Director & CFO
Arpit J Vyas
Independent Director
Subir Kumar Das
Company Sec. & Compli. Officer
Shrima Dave
Independent Director
Margie S Parikh
Independent Director
Hemant J Bhatt
Dishman Corporate House,
Iscon-Bopal Road Ambli,
Gujarat - 380058
Tel: 91-2717-400102/124
Website: http://www.dishmangroup.com
Email: grievance@dishmangroup.com
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: paytm.ipo@linkintime.co.in
Summary
Dishman Carbogen Amcis Limited was formerly incorporated as Carbogen Amcis (India) Limited on July 17, 2007. The Company name later on, was changed to Dishman Carbogen Amcis Limited on 27 March 2017. ...
Read More
Reports by Dishman Carbogen Amcis Ltd
What is the Dishman Carbogen Amcis Ltd share price today?
What is the Market Cap of Dishman Carbogen Amcis Ltd?
What is the PE and PB ratio of Dishman Carbogen Amcis Ltd?
What is the 52 Week High and Low of Dishman Carbogen Amcis Ltd?
What is the CAGR of Dishman Carbogen Amcis Ltd?
What is the shareholding pattern of Dishman Carbogen Amcis Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.